Navigation Links
BioDelivery Sciences Announces Results from Phase 3 Efficacy Study for BEMA Buprenorphine in Chronic Pain
Date:9/28/2011

the product of $500 million in annual peak sales should not change based on the delay this outcome creates, and we will continue our ongoing partnering discussions in earnest, including the sharing of these results, which we believe should be viewed positively.  We anticipate our partner discussions will also aid us in refining the design for our next study.  In summary, we firmly believe that the future of BEMA Buprenorphine for chronic pain, and for our company in general remains bright."

"Moreover, our stockholders should not lose sight of our equally exciting BEMA Buprenorphine/Naloxone product for the treatment of opioid dependence.  We plan to initiate our pivotal bioequivalence trial by the end of this year with data expected in the first quarter of 2012.  It is important to remember that BDSI growth potential is not dependent on one product and that we will continue to develop our promising product opportunities," concluded Dr. Sirgo.

About the Phase 3 BEMA Buprenorphine Trial

The Phase 3 clinical trial (BUP-301) was an enriched-enrollment, double-blind, randomized withdrawal study to evaluate the efficacy and safety of BEMA Buprenorphine in the treatment of chronic lower back pain in opioid naive and experienced patients.  A total of 334 patients enrolled in the trial.  Patients who titrated to an effective and tolerated dose were randomized to either continue on that dose of BEMA Buprenorphine, or be randomized to placebo (BEMA film with no active drug), with treatment continuing for 12 weeks.  The primary efficacy endpoint was the difference in pain intensity scores (on a numerical rating scale of 0 to 11) from the time patients were randomized to receive either BEMA Buprenorphine or placebo to week twelve.

Conference Call Information

BioDelivery Sciences will hold a webcast on Thursday, September 29, at 8:30 AM Eastern Time to discuss the results of this study.  In
'/>"/>

SOURCE BioDelivery Sciences International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related biology technology :

1. BioDelivery Sciences Announces Completion of BEMA Buprenorphine Phase 3 Chronic Pain Study
2. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2008
3. Carna Biosciences Signs Reagent Supply Agreement with Caliper Life Sciences
4. Pressure BioSciences, Inc. to Discuss Second Quarter 2008 Financial Results and Provide Business Update
5. Advanced Life Sciences Awarded U.S. Department of Defense Biodefense Contract Valued at up to $3.8 Million
6. Derma Sciences Reports Second Quarter 2008 Results
7. Advanced Life Sciences Announces Second Quarter 2008 Financial Results
8. The Michigan Life Sciences Pipeline Adds More Resources On Its Website
9. Milestone Biosciences, LLC Further Strengthens Executive Management Team
10. Pressure BioSciences, Inc. Reports Second Quarter 2008 Financial Results and Provides Business Update
11. Access Pharmaceuticals Licenses MuGard to Milestone Biosciences, LLC for North America
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... May 22, 2013  Superior Controls, Inc. has ... by Business NH Magazine.  For the past 22 ... that distinguish themselves with extraordinary business and civic ... receive this honor," said Rick Pierro ... any recognition, this award is a reflection of ...
(Date:5/22/2013)... -- Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that the Company ... Microcap Conference, May 30, in New York, NY ... , CPA, Chief Financial Officer of Cleveland BioLabs, will present ... 1:30 p.m. Eastern Time.  A live and archived webcast of ... of the Cleveland BioLabs website at www.cbiolabs.com . ...
(Date:5/22/2013)... 2013 Express Diagnostics Int’l, Inc. ... are pleased to announce a sponsorship agreement with ... New Zealand distributor of DrugCheck® onsite testing devices, manufactured ... in the Austin 400 May 17-19 in Austin, Texas. ... that involves each car of the Erebus Motorsport team ...
(Date:5/22/2013)... 22, 2013 A recent study from ... athletes to find that those who took probiotics were able ... from the study showed that in extreme heat conditions, probiotics ... their adult acne treatment explains what this new ... may help their skin condition. , While researchers tote ...
Breaking Biology Technology:Superior Controls of Seabrook, NH named Business of the Year for 2013 by Business NH Magazine 2Cleveland BioLabs to Present at Second Annual Marcum LLP Microcap Conference 2Australian Distributor of Express Diagnostics Signs Sponsorship Agreement with V8 Supercar Team 2Adult Acne Treatment, Probiotic Action Shares Insight on New Findings Between Probiotics and Heat Tolerance, and What It Means for Acne Sufferers 2
... in Second Pivotal Clinical Trial , WASHINGTON, Nov. ... today announced positive results from BLISS-76, the second of ... for treating systemic lupus. A full presentation of ... Annual Scientific meeting of the American College of Rheumatology. ...
... powder from her ring into wine glasses carelessly left unattended. ... holding a cabochon or faceted gemstone that can be broken ... so large it is rather odd nobody seems to notice ... the "smart capsule" devised in Younan Xia,s laboratory at ...
... DIEGO and INDIANAPOLIS, Oct. 30, 2009 Amylin Pharmaceuticals, Inc., ... LLY ) today announced that the U.S. Food and ... (exenatide) injection. BYETTA is now approved for use as a ... glycemic control in adults with type 2 diabetes. Previously, it ...
Cached Biology Technology:Promise of a New Lupus Treatment Is a Groundbreaking Achievement 2Promise of a New Lupus Treatment Is a Groundbreaking Achievement 3An exquisite container 2An exquisite container 3An exquisite container 4An exquisite container 5BYETTA Approved for Expanded Use as First-Line Treatment for Type 2 Diabetes 2BYETTA Approved for Expanded Use as First-Line Treatment for Type 2 Diabetes 3BYETTA Approved for Expanded Use as First-Line Treatment for Type 2 Diabetes 4BYETTA Approved for Expanded Use as First-Line Treatment for Type 2 Diabetes 5BYETTA Approved for Expanded Use as First-Line Treatment for Type 2 Diabetes 6BYETTA Approved for Expanded Use as First-Line Treatment for Type 2 Diabetes 7
(Date:5/21/2013)... University researchers have developed a new method for ... holes in the cell surface. The technique could ... related biological fields. , Bulk electroporation a ... reversible nanopores in the cell membrane that are ... is an increasingly popular method of cell transfection. ...
(Date:5/21/2013)... new University of Michigan Water Center today awarded ... Great Lakes restoration and protection efforts. , The ... diverse projects, including efforts to track the remediation ... techniques to control non-native weedy plant invasions; study ... fish responses to restoration activities. , The grants ...
(Date:5/21/2013)... Researchers at the University of Illinois at Chicago College of ... and stores fat -- its main energy source -- and ... disease, under a new $2 million, 4-year grant from the ... heart changes how it uses fuel for energy. These changes ... disease and are different in men and women, says E. ...
Breaking Biology News(10 mins):Single-cell transfection tool enables added control for biological studies 2U-M Water Center awards $570K in Great Lakes restoration grants 2U-M Water Center awards $570K in Great Lakes restoration grants 3U-M Water Center awards $570K in Great Lakes restoration grants 4Do men's and women's hearts burn fuel differently? 2
... volume of online scientific data, a new style of ... have a direct impact on scientists and clinicians. ... Biology and Faculty of 1000 Medicine, are each launching ... journals, called F1000 Reports, are unlike existing scientific journals ...
... Harbor, N.Y. Most of the DNA in the nucleus of ... small fraction of these RNA molecules serve as coding templates for ... RNAs (ncRNA), the functions of a scant few are known: they ... way in which DNA is packaged within cells. What the rest ...
... Park Zoo post-doctoral researcher Carson Murray, Ph.D. has received ... the world,s foremost medical research centers, the National Institutes ... and Rachel Santymire, Ph.D. of Lincoln Park Zoo and ... work to identify stressors of wild female chimpanzees and ...
Cached Biology News:World's experts identify the hottest trends in biology and medicine 2CSHL researchers pinpoint structure-building role for 2 non-coding RNAs 2CSHL researchers pinpoint structure-building role for 2 non-coding RNAs 3Lincoln Park Zoo scientists awarded National Institutes of Health grant 2